Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis

Biomaterials

Volumn 31, Issue 34, 2010, Pages 9057-9064

  Kim, Yu Jeong ^a   Chae, Su Young ^b   Jin, Cheng Hao ^b   Sivasubramanian, M ^a   Son, Sohee ^b   Choi, Ki Young ^a,c   Jo, Dong Gyu ^b   Kim, Kwangmeyung ^c   Chan Kwon, Ick ^c   Lee, Kang Choon ^b   Park, Jae Hyung ^a  

^a Kyung Hee University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

Hyaluronic acid; Nanocomplex; PEG TRAIL; Protein delivery; Rheumatoid arthritis

Indexed keywords

HYALURONIC ACIDS; NANOCOMPLEXES; PEG-TRAIL; PROTEIN DELIVERY; RHEUMATOID ARTHRITIS;

ANTIBODIES; CELL DEATH; COLLAGEN; LIGANDS; ORGANIC ACIDS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES;

HEALTH;

HYALURONIC ACID; MACROGOL; NANOMATERIAL; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNIZATION; IN VIVO STUDY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CYTOKINES; DIFFUSION; HUMANS; HYALURONIC ACID; IONS; KINETICS; KNEE JOINT; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NANOSTRUCTURES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SPLEEN; TISSUE DISTRIBUTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

MUS;

EID: 77957313563     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.08.015     Document Type: Article

References (34)

1. Feldmann M., Brennan F.M., Maini R.N. Rheumatoid arthritis. Cell 1996, 85:307-310.
2. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2(3):214-221.
3. Lee D.M., Weinblatt M.E. Rheumatoid arthritis. Lancet 2001, 358:903-911.
4. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
5. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7:429-442.
6. Maini R.N., Taylor P.C. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000, 51:207-229.
7. Firestein G.S., Zvaifler N.J. Anticytokine therapy in rheumatoid arthritis. N Engl J Med 1997, 337:195-197.
8. Tsokos G.C., Tsokos M. The TRAIL to arthritis. J Clin Invest 2003, 112(9):1315-1317.
9. Griffith T.S., Lynch D.H. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998, 10(5):559-563.
10. Ashkenazi A., Dixit V.M. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999, 11(2):255-260.
11. Ashkenazi A., Dixit V.M. Death receptors: signalling and modulation. Science 1998, 281(5381):1305-1308.
12. Evans C.H. On the TRAIL of an arthritis cure. Gene Ther 2004, 11:735-736.
13. Mackay F., Kalled S.L. TNF ligands and receptors in autoimmunity: an update. Curr Opin Immunol 2002, 14:783-790.
14. Bremer E., van Dam G., Kroesen B.J., de leij L., Helfrich W. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 2006, 12(8):382-393.
15. Rowinsky E.K. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2006, 23(36):9394-9407.
16. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005, 5:876-885.
17. Ichikawa K., Liu W., Fleck M., Zhang H., Zhao L., Ohtsuka T., et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003, 171:1061-1069.
18. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J., et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001, 299(1):31-38.
19. Veronese F.M., Paust G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10:1451-1458.
20. Chae S.Y., Kim T.H., Park K., Jin C.H., Son S., Lee S., et al. Improved antitumor activity and tumor targeting of N-terminal specific PEGylated tumor necrosis factor-related apoptosis inducing ligand. Mol Cancer Ther 2010, 9:1719-1729.
21. Youn Y.S., Shin M.J., Chae S.Y., Jin C.H., Kim T.H., Lee K.C. Biological and physiochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biotechnol Lett 2007, 29(5):713-721.
22. Putney S.D., Burke P.A. Improving protein therapeutics with sustained release formulations. Nat Biotechnol 1998, 16:153-157.
23. Lee E.S., Park K.H., Kang D., Park I.S., Min H.Y., Lee D.H., et al. Protein complexed with chondroitin sulfate in poly(lactide-co-glycolide) microspheres. Biomaterials 2007, 28:2754-2762.
24. Liu Z., Jiao Y., Wang Y., Zhou C., Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliver Rev 2008, 60:1650-1662.
25. Janes K.A., Calvo P., Alonso M.J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliver Rev 2001, 47:83-97.
26. Na S.J., Chae S.Y., Lee S., Park K., Kim K., Park J.H., et al. Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand. Int J Pharm 2008, 363:149-154.
27. Gura T. How TRAIL kills cancer cells, but not normal cells. Science 1997, 277:768.
28. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008, 7:1001-1012.
29. Toyama S., Tamura N., Haruta K., Karakida T., Mori S., Watanabe T., et al. Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice. Arthritis Res Ther 2010, 12(3):R92.
30. Zheng X., Suzuki M., Ichim T.E., Zhang X., Sun H., Zhu F., et al. Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol 2010, 184(11):6457-6464.
31. Luross J.A., Williams N.A. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001, 103(4):407-416.
32. Snapper C.M., Peschel C., Paul W.E. IFN-gamma stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J Immunol 1988, 140(7):2121-2127.
33. Johnson O.L., Cleland J.L., Lee H.J., Charnis M., Duenas E., Jaworowicz W., et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med 1996, 2:795-799.
34. Fu K., Pack D.W., Klibanov A.M., Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 2000, 17(1):100-106.